Nanotechnology Now

Our NanoNews Digest Sponsors
Heifer International

Wikipedia Affiliate Button

Home > Press > Arrowhead Pharmaceuticals Receives FDA Clearance to Begin Phase 2/3 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease

Abstract:
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has received clearance from the U.S. Food and Drug Administration to proceed with an adaptive Phase 2/3 trial with the potential to serve as a pivotal registrational study of ARO-AAT, the company’s second generation subcutaneously administered RNA interference (RNAi) therapeutic being developed as a treatment for a rare genetic liver disease associated with alpha-1 antitrypsin deficiency (AATD).

Arrowhead Pharmaceuticals Receives FDA Clearance to Begin Phase 2/3 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease

Pasadena. CA | Posted on April 15th, 2019

Arrowhead intends to initiate the adaptive design, Phase 2/3 study of ARO-AAT in patients with AATD associated liver disease at various sites in the U.S. in the second quarter of 2019, followed by various international sites in Europe, pending regulatory submission and review. The proposed primary objectives are to evaluate safety and pharmacodynamic dose response, and to evaluate efficacy, defined as an improvement in a histologic grading scale of AATD associated liver disease, and no worsening of liver fibrosis based on Ishak score on end of study biopsy. The company plans to provide additional study details following its initiation.

####

About Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing.

For more information, please visit www.arrowheadpharma.com, or follow us on Twitter @ArrowheadPharma. To be added to the Company's email list and receive news directly, please visit http://ir.arrowheadpharma.com/email-alerts .

Safe Harbor Statement under the Private Securities Litigation Reform Act:

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the safety and efficacy of our product candidates, the duration and impact of regulatory delays in our clinical programs, our ability to finance our operations, the likelihood and timing of the receipt of future milestone and licensing fees, the future success of our scientific studies, our ability to successfully develop and commercialize drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, and the enforcement of our intellectual property rights. Our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q discuss some of the important risk factors that may affect our business, results of operations and financial condition. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances.

For more information, please click here

Contacts:
Arrowhead Pharmaceuticals, Inc.
Vince Anzalone, CFA
626-304-3400


Investors and Media:
LifeSci Advisors, LLC
Brian Ritchie
212-915-2578

www.lifesciadvisors.com

Copyright © Arrowhead Pharmaceuticals, Inc.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Oxford Instruments announces release of new dilution refrigerator - Proteox: Opening the door for a new direction in dilution refrigerator development February 28th, 2020

Breaking the temperature barrier in small-scale materials testing February 28th, 2020

An 'exceptionally stable' single-atom catalyst: Single platinum atoms stabilized in C12A7 crystals February 26th, 2020

180 Degree Capital Corp. Reports 15.9% Annual Increase and 0.3% Quarter Increase in Net Asset Value Per Share to $3.06 as of December 31, 2019 February 24th, 2020

Govt.-Legislation/Regulation/Funding/Policy

Black phosphorous tunnel field-effect transistor as an alternative ultra-low power switch? February 21st, 2020

Researchers show what drives a novel, ordered assembly of alternating peptides February 20th, 2020

KIST unveils the mystery of van der Waals magnets, a material for future semiconductors: Overcoming the limits of current magnetic materials, giving hope for development of next-generation semiconductors February 14th, 2020

Nanotech company granted FDA Fast Track for treatment of head & neck cancer February 10th, 2020

Nanomedicine

A scaffold at the center of our cellular skeleton: UNIGE researchers have discovered a new nano-structure that lies at the center of our cellular skeleton; this discovery will allow to better understand how the cell maintains its architecture as well as the pathologies associated February 21st, 2020

Novel formulation permits use of toxin from rattlesnake venom to treat chronic pain: Researchers Butantan Institute succeeded in reducing the toxicity and potentiating the analgesic effect of crotoxin by encapsulating it in nanostructured silica -- the results of tests in an anim February 14th, 2020

Gold nanoclusters: new frontier for developing medication for treatment of Alzheimer's disease February 14th, 2020

Nanotech company granted FDA Fast Track for treatment of head & neck cancer February 10th, 2020

Discoveries

Breaking the temperature barrier in small-scale materials testing February 28th, 2020

An 'exceptionally stable' single-atom catalyst: Single platinum atoms stabilized in C12A7 crystals February 26th, 2020

The Human Brain/Cloud Interface Research Paper has been Published! February 22nd, 2020

Russian scientists found an effective way to obtain fuel for hydrogen engines: One of the most promising alternative energy sources is hydrogen, which can be extracted from water and air February 21st, 2020

Announcements

Oxford Instruments announces release of new dilution refrigerator - Proteox: Opening the door for a new direction in dilution refrigerator development February 28th, 2020

Breaking the temperature barrier in small-scale materials testing February 28th, 2020

An 'exceptionally stable' single-atom catalyst: Single platinum atoms stabilized in C12A7 crystals February 26th, 2020

180 Degree Capital Corp. Reports 15.9% Annual Increase and 0.3% Quarter Increase in Net Asset Value Per Share to $3.06 as of December 31, 2019 February 24th, 2020

Nanobiotechnology

Novel formulation permits use of toxin from rattlesnake venom to treat chronic pain: Researchers Butantan Institute succeeded in reducing the toxicity and potentiating the analgesic effect of crotoxin by encapsulating it in nanostructured silica -- the results of tests in an anim February 14th, 2020

Gold nanoclusters: new frontier for developing medication for treatment of Alzheimer's disease February 14th, 2020

Nanotech company granted FDA Fast Track for treatment of head & neck cancer February 10th, 2020

Arrowhead Reports Interim Clinical Data on Cardiometabolic Candidates ARO-APOC3 and ARO-ANG3 February 5th, 2020

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project